Tri Locum Partners L.P. is an investment fund managing more than $288 billion ran by Christabel Syham. There are currently 25 companies in Syham’s portfolio. The largest investments include Teva Pharmaceutical Inds Ltd and Argenx Se, together worth $73.5 billion.
As of 7th August 2024, Tri Locum Partners L.P.’s top holding is 2,550,307 shares of Teva Pharmaceutical Inds Ltd currently worth over $41.4 billion and making up 10.5% of the portfolio value.
In addition, the fund holds 74,558 shares of Argenx Se worth $32.1 billion.
The third-largest holding is Ascendis Pharma A/S worth $31.1 billion and the next is AMGEN worth $25.7 billion, with 82,271 shares owned.
Currently, Tri Locum Partners L.P.'s portfolio is worth at least $288 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Tri Locum Partners L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Christabel Syham serves as the Chief Compliance Officer at Tri Locum Partners L.P..
In the most recent 13F filing, Tri Locum Partners L.P. revealed that it had opened a new position in
AMGEN and bought 82,271 shares worth $25.7 billion.
This means they effectively own approximately 0.1% of the company.
AMGEN makes up
9.0%
of the fund's Health Care sector allocation and has grown its share price by 23.9% in the past year.
The investment fund also strengthened its position in Teva Pharmaceutical Inds Ltd by buying
334,119 additional shares.
This makes their stake in Teva Pharmaceutical Inds Ltd total 2,550,307 shares worth $41.4 billion.
On the other hand, there are companies that Tri Locum Partners L.P. is getting rid of from its portfolio.
Tri Locum Partners L.P. closed its position in Silk Rd Med Inc on 14th August 2024.
It sold the previously owned 1,083,605 shares for $19.9 billion.
Christabel Syham also disclosed a decreased stake in Xenon Pharmaceuticals Inc by 0.5%.
This leaves the value of the investment at $3.98 billion and 101,959 shares.
The two most similar investment funds to Tri Locum Partners L.P. are Castle Rock Wealth Management and Versant Capital Management, Inc. They manage $395 billion and $395 billion respectively.
Tri Locum Partners L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 72.5% of
the total portfolio value.
The fund focuses on investments in the United States as
48.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
20% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $35.6 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Teva Pharmaceutical Inds Ltd |
15.08%
2,550,307
|
$41,442,489,000 | 10.48% |
| Argenx Se |
166.46%
74,558
|
$32,062,922,000 | 8.11% |
| Ascendis Pharma A/S |
102.15%
227,762
|
$31,062,182,000 | 7.85% |
| AMGEN Inc. |
Opened
82,271
|
$25,705,574,000 | 6.50% |
| Natera Inc |
21.29%
230,585
|
$24,970,050,000 | 6.31% |
| Axsome Therapeutics Inc |
198.42%
306,513
|
$24,674,297,000 | 6.24% |
| Insmed Inc |
Opened
316,501
|
$21,205,567,000 | 5.36% |
| Merus N.V |
17.18%
335,514
|
$19,852,363,000 | 5.02% |
| Silk Rd Med Inc |
Closed
1,083,605
|
$19,851,644,000 | |
| Regeneron Pharmaceuticals, Inc. |
104.46%
17,516
|
$18,409,841,000 | 4.65% |
| Madrigal Pharmaceuticals Inc |
22.49%
65,352
|
$18,309,016,000 | 4.63% |
| Inspire Med Sys Inc |
465.54%
133,276
|
$17,836,327,000 | 4.51% |
| Avadel Pharmaceuticals plc |
0.00%
1,189,518
|
$16,724,623,000 | 4.23% |
| Pfizer Inc. |
Opened
596,919
|
$16,701,794,000 | 4.22% |
| United Therapeutics Corp |
Opened
50,100
|
$15,959,355,000 | 4.04% |
| Legend Biotech Corp |
25.64%
356,532
|
$15,790,802,000 | 3.99% |
| Merck Co Inc |
Closed
119,200
|
$15,728,440,000 | |
| Vertex Pharmaceuticals, Inc. |
Closed
35,598
|
$14,880,320,000 | |
| Baxter International Inc. |
Closed
317,566
|
$13,572,771,000 | |
| Tandem Diabetes Care Inc |
Closed
326,506
|
$11,561,577,000 | |
| Alnylam Pharmaceuticals Inc |
Opened
45,000
|
$10,935,000,000 | 2.76% |
| Stevanato Group S.p.A. |
Opened
565,422
|
$10,369,839,000 | 2.62% |
| Novo-nordisk A S |
Opened
63,811
|
$9,108,382,000 | 2.30% |
| Vaxcyte, Inc. |
Opened
113,344
|
$8,558,605,000 | 2.16% |
| Exact Sciences Corp. |
Closed
90,000
|
$6,215,400,000 | |
| Lyra Therapeutics, Inc. |
Closed
978,793
|
$6,088,092,000 | |
| Astria Therapeutics Inc |
Closed
369,549
|
$5,201,402,000 | |
| Alpine Immune Sciences Inc |
Closed
120,687
|
$4,784,033,000 | |
| Arcturus Therapeutics Hldgs |
Closed
138,927
|
$4,691,565,000 | |
| Arcutis Biotherapeutics Inc |
Closed
449,694
|
$4,456,468,000 | |
| Xenon Pharmaceuticals Inc |
50.85%
101,959
|
$3,975,381,000 | 1.01% |
| Ocular Therapeutix Inc |
Opened
514,642
|
$3,520,151,000 | 0.89% |
| Praxis Precision Medicines I |
29.27%
75,319
|
$3,115,194,000 | 0.79% |
| Mind Medicine Mindmed Inc |
0.65%
382,055
|
$2,754,617,000 | 0.70% |
| Korro Bio Inc |
Opened
71,428
|
$2,419,266,000 | 0.61% |
| Perspective Therapeutics Inc |
Closed
780,303
|
$928,561,000 | |
| Femasys Inc |
No change
30,606
|
$34,891,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 37 holdings | |||